Current Role of Lipoprotein Apheresis

Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)

(2019) Elisa Waldmann et al.   PATHOLOGY

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans

(2018) Gilbert R. Thompson   ATHEROSCLEROSIS

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

(2018) Antonio J. Vallejo-Vaz et al.   ATHEROSCLEROSIS

Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort

(2018) Sophie Beliard et al.   ATHEROSCLEROSIS

Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study

(2018) Federico Bigazzi et al.   TRANSFUSION AND APHERESIS SCIENCE

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

(2017) Gilbert R Thompson et al.   EUROPEAN HEART JOURNAL

Homozygous familial hypercholesterolaemia: light at the end of the tunnel

(2017) Robert M Stoekenbroek et al.   EUROPEAN HEART JOURNAL

Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis

(2017) Shazia Nakhoda et al.   TRANSFUSION AND APHERESIS SCIENCE

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

(2017) Frederick J Raal et al.   Lancet Diabetes & Endocrinology

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom

(2016) Michael France et al.   ATHEROSCLEROSIS

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

Lipoprotein apheresis to treat elevated lipoprotein (a)

(2016) Elisa Waldmann et al.   JOURNAL OF LIPID RESEARCH

Double Filtration Plasma Apheresis Shortens Hospital Admission Duration of Patients With Severe Hypertriglyceridemia-Associated Acute Pancreatitis

(2016) Chiz-Tzung Chang et al.   PANCREAS

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia

(2016) Anthony Wang et al.   Journal of the American Heart Association

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trial

(2015) C. Stefanutti et al.   ATHEROSCLEROSIS

Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes

(2015) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia

(2015) Bruno Lefort et al.   ATHEROSCLEROSIS

Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

(2015) Jean-Philippe Drouin-Chartier et al.   JOURNAL OF CLINICAL APHERESIS

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances

(2014) Claudia Stefanutti et al.   Current Atherosclerosis Reports

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?

(2013) Adrian Rosada et al.   ARTIFICIAL ORGANS

Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography

(2013) Maya S. Safarova et al.   ATHEROSCLEROSIS SUPPLEMENTS

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

(2013) Gerald F. Watts et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Guidelines for the Management of Familial Hypercholesterolemia

(2012) Mariko Harada-Shiba et al.   Journal of Atherosclerosis and Thrombosis

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

(2011) Anne C. Goldberg et al.   Journal of Clinical Lipidology

Lipid Apheresis by Hemoperfusion: In Vitro Efficacy and Ex Vivo Biocompatibility of a New Low-Density Lipoprotein Adsorber Compatible with Human Whole Blood

(2010) T. Bosch et al.   ARTIFICIAL ORGANS

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American Society for Apheresis

(2010) Zbigniew M. Szczepiorkowski et al.   JOURNAL OF CLINICAL APHERESIS

Efficacy criteria and cholesterol targets for LDL apheresis

(2009) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Recommendations for the use of LDL apheresis

(2008) G.R. Thompson   ATHEROSCLEROSIS